ReviewMolecular biology reports2026
Metal nanoparticles as next-generation therapeutics against antimicrobial resistance: mechanisms, functionalization, and translational potential.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance (AMR) poses a major global health threat, driven by bacterial defense mechanisms such as efflux pumps, enzyme-mediated drug inactivation, target site modification, and biofilm formation. Metal nanoparticles (NPs), including silver, gold, iron oxide, and zinc oxide, offer a potential multi-target strategy to dismantle these resistance pathways. Their antimicrobial activity stems from direct membrane disruption, induction of oxidative stress, and, crucially, the modulation of bacterial gene expression, including downregulation of efflux pump and biofilm-related genes and disruption of quorum-sensing networks. The efficacy and specificity of NPs are significantly enhanced through advanced functionalization strategies, such as organic ligand conjugation, antibody coupling, and green synthesis approaches using biological resources, enabling targeted drug delivery and reduced off-target toxicity. Despite promising translational applications in antimicrobial coatings, wound dressings, and adjuvant therapies, clinical adoption faces hurdles including potential cytotoxicity, unpredictable pharmacokinetics, and the need for standardized manufacturing. Future directions involve the development of environmentally responsive "smart" NPs, nanoparticle-mediated delivery of siRNA to suppress resistance genes, and the integration of multi-omics approaches to decipher NP-bacteria interactions at the molecular level. Collectively, engineered metal NPs represent a promising platform for next-generation antimicrobial strategies and may help address multidrug resistance through simultaneous molecular and physical effects.
Indexed as
Identifiers
42700201What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.